Christopher Posner, President and CEO at Cara Therapeutics, Inc. (CARA), sold 2,006 shares at $12.67 ($25K) on 2022-04-04, disclosed to the SEC on 2022-04-05.
Scheduled sale ($25k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CARA | SELL | 2024-11-06 | $1K | — | Filing → |
| CARA | SELL | 2024-08-02 | $1K | — | Filing → |
| CARA | SELL | 2024-05-06 | $3K | — | Filing → |